Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

a technology combination drugs, which is applied in the direction of heterocyclic compound active ingredients, drug compositions, organic active ingredients, etc., can solve problems such as resistance and achieve the effect of reducing the ras-gtp loading potential of cells and amplifying the anti-proliferation effect of anaplastic lymphoma kinas
US20190343836A1Inactive Publication Date: 2019-11-14THE GENERAL HOSPITAL CORP +1
0 Cites 5 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
THE GENERAL HOSPITAL CORP
Publication Date
2019-11-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present invention relates to a pharmaceutical combination comprising an anaplastic lymphoma kinase (ALK) inhibitor as one of the combination partners, the uses of such a combination in the treatment of proliferative diseases, such as cancer, in particular non-small cell lung cancer (NSCLC); and methods of treating a subject suffering from a proliferative disease, such as cancer, in particular non-small cell lung cancer, comprising administering a therapeutically effective amount of such a combination.BACKGROUND OF THE INVENTION

[0002] Highly potent and selective inhibitors targeting anaplastic lymphoma kinase (ALK)-rearranged lung cancer have been used to treat patients suffering from non-small cell lung cancer (NSCLC). However, in spite of these treatment options cases of resistance occur. The resistance to the selective inhibitors can develops through a variety of mechanisms, such as for example through secondary mutations in ALK, or activation of a c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More